-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Yifan Pharmaceutical (002019.SZ) announced that the holding subsidiaries of the company, Yiyi Biomedical Development (Shanghai) Co., Ltd., Yiyi Biopharmaceutical (Beijing) Co., Ltd. (the above subsidiaries are collectively referred to as “Ebio-Biotech”), have recently received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration and agreed that Yiyi Biotech is injecting recombinant human interleukin 22-Fc fusion protein (“F-652”) into the product under development to carry out phase II clinical trials for the treatment of graft-versus-host disease (GVHD).

Zhitongcaijing·01/05/2026 09:49:08
Listen to the news
Zhitong Finance App News, Yifan Pharmaceutical (002019.SZ) announced that the holding subsidiaries of the company, Yiyi Biomedical Development (Shanghai) Co., Ltd., Yiyi Biopharmaceutical (Beijing) Co., Ltd. (the above subsidiaries are collectively referred to as “Ebio-Biotech”), have recently received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration and agreed that Yiyi Biotech is injecting recombinant human interleukin 22-Fc fusion protein (“F-652”) into the product under development to carry out phase II clinical trials for the treatment of graft-versus-host disease (GVHD).